Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000079018 | SCV000110887 | benign | not specified | 2013-11-14 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000079018 | SCV000917403 | benign | not specified | 2017-10-30 | criteria provided, single submitter | clinical testing | Variant summary: The GALNS c.1002+17C>T variant involves the alteration of a non-conserved intronic nucleotide and 5/5 splice prediction tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. This variant was found in 862/272430 (23 homozygotes) control chromosomes (gnomAD), predominantly observed in the African subpopulation at a frequency of 0.033904 (800/23596, 22 homozygotes). This frequency is about 17 times the estimated maximal expected allele frequency of a pathogenic GALNS variant (0.0020412), suggesting this is likely a benign polymorphism found primarily in the populations of African origin. In addition, a clinical diagnostic laboratory classified this variant as benign. Taken together, this variant is classified as benign. |
Labcorp Genetics |
RCV001520916 | SCV001730131 | benign | Mucopolysaccharidosis, MPS-IV-A | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001520916 | SCV002045054 | benign | Mucopolysaccharidosis, MPS-IV-A | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000675533 | SCV005252589 | benign | not provided | criteria provided, single submitter | not provided | ||
Mayo Clinic Laboratories, |
RCV000675533 | SCV000801224 | likely benign | not provided | 2017-05-01 | no assertion criteria provided | clinical testing |